The role of procalcitonin as a biomarker for acute pulmonary exacerbation in subjects with cystic fibrosis and non-cystic fibrosis bronchiectasis

Authors : Firuz MAMMADOV, Sehnaz OLGUN YILDIZELI, Derya KOCAKAYA, Huseyin ARIKAN, Caner ÇINAR, Emel ERYUKSEL, Berrin CEYHAN

Pages : 164-171

Doi:10.5472/marumj.1114952

View : 11 | Download : 5

Publication Date : 2022-05-30

Article Type : Research Paper

Abstract :Objective: Patients with cystic fibrosis insert ignore into journalissuearticles values(CF); and non-CF bronchiectasis are prone to exacerbations of pulmonary infections. C-reactive protein insert ignore into journalissuearticles values(CRP); and procalcitonin insert ignore into journalissuearticles values(PCT); are inflammatory markers. The aim of this study is to evaluate the role of CRP and PCT on exacerbations of CF and non-CF bronchiectasis. Patients and Methods: The medical records of 18 CF insert ignore into journalissuearticles values(52 hospitalizations); and 20 non-CF bronchiectasis patients insert ignore into journalissuearticles values(51 hospitalizations); were reviewed retrospectively. CRP, PCT levels and, white blood cell insert ignore into journalissuearticles values(WBC); counts on admission and follow-up were evaluated. Results: C-reactive protein levels correlated with PCT levels on admission in all patients. Baseline PCT levels were markedly higher insert ignore into journalissuearticles values(>0.5µg/L); in 12% of CF and 10% of non-CF bronchiectasis patients, however, baseline CRP values were markedly higher insert ignore into journalissuearticles values(>5mg/L); in 96% of CF and non-CF bronchiectasis patients insert ignore into journalissuearticles values(p=0.760 and p=0.100, respectively);. Baseline CRP and PCT levels were positively correlated with hospitalization length insert ignore into journalissuearticles values(r=0.501, p=0.001 and r=0.289, p=0.04, respectively); in CF patients, but not in non-CF bronchiectasis. Conclusion: Our study shows the potential utility of these biomarkers to determine the severity of the exacerbation particularly predicting hospitalization length in CF patients. Both biomarkers could be able to guide antibiotic treatment of infective exacerbations in CF and non-CF bronchiectasis patients
Keywords : Cystic fibrosis, Bronchiectasis, Exacerbation, Infection, Procalcitonin, C reactive protein